Community pharmaceuticals: Expenditure trends
Siddharth, Prince; Hogan, Sarah | September 2017
This report describes the analysis of trends in the CPB and the community pharmaceutical expenditure component of the CPB. This expenditure data was based on publicly available information from Vote Health Budget Estimates, Official Information Act (OIA) responses received by Medicines New Zealand from PHARMAC and press statements from the Minister of Health on PHARMAC budgets (2017 and 2018) but was checked for accuracy against PHARMAC annual reports and, in the case of Vote Health estimates, against estimates published on the NZ Treasury website. The objective of the analysis was to identify changes in the absolute and relative levels of expenditure on the CPB and community pharmaceuticals net of rebates and movements in the Discretionary Pharmaceutical Fund (DPF), taking into account inflation and population growth, and in comparison with other measures of health expenditure. The analysis does not assume that there is a ‘right’ amount to spend on pharmaceuticals, but intends only to provide good information for decision-making. The analysis also did not include any consideration of: outcomes of pharmaceutical investment; effectiveness of PHARMAC’s functions or of funded pharmaceuticals; effects of changes in the price of pharmaceuticals; the level of need for funded pharmaceuticals; or changes in the specific composition of community pharmaceutical expenditure. Interpretation of results may require that these additional issues be considered.
CitationSiddharth, Prince; Hogan, Sarah. 2017. Community pharmaceuticals: Expenditure trends. © New Zealand Institute of Economic Research. http://hdl.handle.net/11540/7876.
Public Health Administration
Health Care Pricing
Health Care Cost Control
Education, Health and Social Protection
Long Term Care Insurance
Public health records
Cost of medical care
Delivery of health care
Medical and health care industryShow allCollapse